Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

IRIX vs ARAY vs ISRG vs GKOS vs SYK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
IRIX
IRIDEX Corporation

Medical - Devices

HealthcareNASDAQ • US
Market Cap$18M
5Y Perf.-42.8%
ARAY
Accuray Incorporated

Medical - Devices

HealthcareNASDAQ • US
Market Cap$45M
5Y Perf.-81.9%
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$159.85B
5Y Perf.+132.8%
GKOS
Glaukos Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$7.81B
5Y Perf.+242.5%
SYK
Stryker Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$109.33B
5Y Perf.+45.8%

IRIX vs ARAY vs ISRG vs GKOS vs SYK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
IRIX logoIRIX
ARAY logoARAY
ISRG logoISRG
GKOS logoGKOS
SYK logoSYK
IndustryMedical - DevicesMedical - DevicesMedical - Instruments & SuppliesMedical - DevicesMedical - Devices
Market Cap$18M$45M$159.85B$7.81B$109.33B
Revenue (TTM)$51M$429M$10.58B$551M$25.12B
Net Income (TTM)$-5M$-46M$2.98B$-189M$3.25B
Gross Margin38.0%26.8%66.3%78.1%63.5%
Operating Margin-6.0%-3.5%30.5%-15.6%22.4%
Forward P/E43.3x19.1x
Total Debt$5M$176M$303M$140M$14.86B
Cash & Equiv.$2M$57M$3.37B$91M$4.01B

IRIX vs ARAY vs ISRG vs GKOS vs SYKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

IRIX
ARAY
ISRG
GKOS
SYK
StockMay 20May 26Return
IRIDEX Corporation (IRIX)10057.2-42.8%
Accuray Incorporated (ARAY)10018.1-81.9%
Intuitive Surgical,… (ISRG)100232.8+132.8%
Glaukos Corporation (GKOS)100342.5+242.5%
Stryker Corporation (SYK)100145.8+45.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: IRIX vs ARAY vs ISRG vs GKOS vs SYK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: SYK leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Intuitive Surgical, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. GKOS also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
IRIX
IRIDEX Corporation
The Healthcare Pick

IRIX lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
ARAY
Accuray Incorporated
The Healthcare Pick

Among these 5 stocks, ARAY doesn't own a clear edge in any measured category.

Best for: healthcare exposure
ISRG
Intuitive Surgical, Inc.
The Growth Play

ISRG is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
  • 5.5% 10Y total return vs GKOS's 454.5%
  • Lower volatility, beta 1.00, Low D/E 1.7%, current ratio 4.87x
  • Beta 1.00, current ratio 4.87x
Best for: growth exposure and long-term compounding
GKOS
Glaukos Corporation
The Growth Leader

GKOS ranks third and is worth considering specifically for growth and momentum.

  • 32.3% revenue growth vs IRIX's -6.2%
  • +47.5% vs ARAY's -74.5%
Best for: growth and momentum
SYK
Stryker Corporation
The Income Pick

SYK carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.

  • Dividend streak 34 yrs, beta 0.52, yield 1.2%
  • PEG 1.28 vs ISRG's 1.99
  • Better valuation composite
  • Beta 0.52 vs ARAY's 2.66, lower leverage
Best for: income & stability and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthGKOS logoGKOS32.3% revenue growth vs IRIX's -6.2%
ValueSYK logoSYKBetter valuation composite
Quality / MarginsISRG logoISRG28.2% margin vs GKOS's -34.3%
Stability / SafetySYK logoSYKBeta 0.52 vs ARAY's 2.66, lower leverage
DividendsSYK logoSYK1.2% yield; 34-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)GKOS logoGKOS+47.5% vs ARAY's -74.5%
Efficiency (ROA)ISRG logoISRG14.8% ROA vs GKOS's -20.1%, ROIC 15.0% vs -9.2%

IRIX vs ARAY vs ISRG vs GKOS vs SYK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

IRIXIRIDEX Corporation
FY 2024
Retina
57.2%$28M
Cyclo G Six
26.1%$13M
Product and Service, Other
16.7%$8M
ARAYAccuray Incorporated
FY 2025
Product
51.8%$238M
Service
48.2%$221M
ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B
GKOSGlaukos Corporation
FY 2019
Glaucoma
97.5%$231M
Corneal Health
2.5%$6M
SYKStryker Corporation
FY 2025
MedSurg
62.3%$15.6B
Orthopaedics
37.7%$9.5B

IRIX vs ARAY vs ISRG vs GKOS vs SYK — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLISRGLAGGINGSYK

Income & Cash Flow (Last 12 Months)

ISRG leads this category, winning 3 of 6 comparable metrics.

SYK is the larger business by revenue, generating $25.1B annually — 495.9x IRIX's $51M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to GKOS's -34.3%. On growth, GKOS holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricIRIX logoIRIXIRIDEX CorporationARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…GKOS logoGKOSGlaukos Corporati…SYK logoSYKStryker Corporati…
RevenueTrailing 12 months$51M$429M$10.6B$551M$25.1B
EBITDAEarnings before interest/tax-$2M-$6M$3.8B-$40M$6.3B
Net IncomeAfter-tax profit-$5M-$46M$3.0B-$189M$3.2B
Free Cash FlowCash after capex-$3M-$29M$2.8B-$18M$4.3B
Gross MarginGross profit ÷ Revenue+38.0%+26.8%+66.3%+78.1%+63.5%
Operating MarginEBIT ÷ Revenue-6.0%-3.5%+30.5%-15.6%+22.4%
Net MarginNet income ÷ Revenue-10.0%-10.8%+28.2%-34.3%+12.9%
FCF MarginFCF ÷ Revenue-5.6%-6.8%+26.8%-3.4%+17.1%
Rev. Growth (YoY)Latest quarter vs prior year+7.8%-7.4%+23.0%+41.2%+11.4%
EPS Growth (YoY)Latest quarter vs prior year+25.0%-6.1%+18.8%-6.3%+56.0%
ISRG leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — ARAY and SYK each lead in 3 of 7 comparable metrics.

At 34.0x trailing earnings, SYK trades at a 41% valuation discount to ISRG's 57.2x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.29x vs ISRG's 2.63x — a lower PEG means you pay less per unit of expected earnings growth.

MetricIRIX logoIRIXIRIDEX CorporationARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…GKOS logoGKOSGlaukos Corporati…SYK logoSYKStryker Corporati…
Market CapShares × price$18M$45M$159.8B$7.8B$109.3B
Enterprise ValueMkt cap + debt − cash$20M$164M$156.8B$7.9B$120.2B
Trailing P/EPrice ÷ TTM EPS-1.91x-24.52x57.19x-40.71x33.98x
Forward P/EPrice ÷ next-FY EPS est.43.35x19.06x
PEG RatioP/E ÷ EPS growth rate2.63x2.29x
EV / EBITDAEnterprise value multiple11.74x43.28x19.76x
Price / SalesMarket cap ÷ Revenue0.36x0.10x15.88x15.40x4.35x
Price / BookPrice ÷ Book value/share8.07x0.48x9.10x11.64x4.87x
Price / FCFMarket cap ÷ FCF64.18x25.53x
Evenly matched — ARAY and SYK each lead in 3 of 7 comparable metrics.

Profitability & Efficiency

ISRG leads this category, winning 7 of 9 comparable metrics.

ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-109 for IRIX. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to IRIX's 2.21x. On the Piotroski fundamental quality scale (0–9), ARAY scores 6/9 vs IRIX's 2/9, reflecting solid financial health.

MetricIRIX logoIRIXIRIDEX CorporationARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…GKOS logoGKOSGlaukos Corporati…SYK logoSYKStryker Corporati…
ROE (TTM)Return on equity-108.7%-77.5%+16.9%-26.5%+15.0%
ROA (TTM)Return on assets-17.9%-10.1%+14.8%-20.1%+6.9%
ROICReturn on invested capital-129.9%+3.0%+15.0%-9.2%+11.4%
ROCEReturn on capital employed-48.8%+2.8%+16.5%-10.3%+13.0%
Piotroski ScoreFundamental quality 0–926636
Debt / EquityFinancial leverage2.21x2.17x0.02x0.21x0.66x
Net DebtTotal debt minus cash$2M$119M-$3.1B$49M$10.8B
Cash & Equiv.Liquid assets$2M$57M$3.4B$91M$4.0B
Total DebtShort + long-term debt$5M$176M$303M$140M$14.9B
Interest CoverageEBIT ÷ Interest expense-0.54x-18.69x6.72x
ISRG leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

GKOS leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in GKOS five years ago would be worth $17,474 today (with dividends reinvested), compared to $880 for ARAY. Over the past 12 months, GKOS leads with a +47.5% total return vs ARAY's -74.5%. The 3-year compound annual growth rate (CAGR) favors GKOS at 31.5% vs ARAY's -52.7% — a key indicator of consistent wealth creation.

MetricIRIX logoIRIXIRIDEX CorporationARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…GKOS logoGKOSGlaukos Corporati…SYK logoSYKStryker Corporati…
YTD ReturnYear-to-date-12.0%-55.3%-19.9%+20.6%-17.8%
1-Year ReturnPast 12 months-9.6%-74.5%-16.4%+47.5%-24.5%
3-Year ReturnCumulative with dividends-54.6%-89.4%+48.5%+127.6%+2.4%
5-Year ReturnCumulative with dividends-86.2%-91.2%+61.7%+74.7%+17.5%
10-Year ReturnCumulative with dividends-90.8%-92.8%+549.2%+454.5%+179.2%
CAGR (3Y)Annualised 3-year return-23.2%-52.7%+14.1%+31.5%+0.8%
GKOS leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — GKOS and SYK each lead in 1 of 2 comparable metrics.

SYK is the less volatile stock with a 0.52 beta — it tends to amplify market swings less than ARAY's 2.66 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GKOS currently trades 91.0% from its 52-week high vs ARAY's 18.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricIRIX logoIRIXIRIDEX CorporationARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…GKOS logoGKOSGlaukos Corporati…SYK logoSYKStryker Corporati…
Beta (5Y)Sensitivity to S&P 5001.16x2.66x1.00x1.16x0.52x
52-Week HighHighest price in past year$1.65$2.10$603.88$146.75$404.87
52-Week LowLowest price in past year$0.87$0.28$427.84$73.16$284.97
% of 52W HighCurrent price vs 52-week peak+62.4%+18.1%+74.5%+91.0%+70.5%
RSI (14)Momentum oscillator 0–10041.633.543.661.526.6
Avg Volume (50D)Average daily shares traded124K1.5M1.8M674K2.1M
Evenly matched — GKOS and SYK each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: ISRG as "Buy", GKOS as "Buy", SYK as "Buy". Consensus price targets imply 38.3% upside for ISRG (target: $623) vs 9.8% for GKOS (target: $147). SYK is the only dividend payer here at 1.18% yield — a key consideration for income-focused portfolios.

MetricIRIX logoIRIXIRIDEX CorporationARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…GKOS logoGKOSGlaukos Corporati…SYK logoSYKStryker Corporati…
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$622.60$146.67$389.62
# AnalystsCovering analysts552450
Dividend YieldAnnual dividend ÷ price+1.2%
Dividend StreakConsecutive years of raises34
Dividend / ShareAnnual DPS$3.36
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+1.4%0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ISRG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). GKOS leads in 1 (Total Returns). 2 tied.

Best OverallIntuitive Surgical, Inc. (ISRG)Leads 2 of 6 categories
Loading custom metrics...

IRIX vs ARAY vs ISRG vs GKOS vs SYK: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is IRIX or ARAY or ISRG or GKOS or SYK a better buy right now?

For growth investors, Glaukos Corporation (GKOS) is the stronger pick with 32.

3% revenue growth year-over-year, versus -6. 2% for IRIDEX Corporation (IRIX). Stryker Corporation (SYK) offers the better valuation at 34. 0x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — IRIX or ARAY or ISRG or GKOS or SYK?

On trailing P/E, Stryker Corporation (SYK) is the cheapest at 34.

0x versus Intuitive Surgical, Inc. at 57. 2x. On forward P/E, Stryker Corporation is actually cheaper at 19. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 28x versus Intuitive Surgical, Inc. 's 1. 99x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — IRIX or ARAY or ISRG or GKOS or SYK?

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +74.

7%, compared to -91. 2% for Accuray Incorporated (ARAY). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus ARAY's -92. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — IRIX or ARAY or ISRG or GKOS or SYK?

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

52β versus Accuray Incorporated's 2. 66β — meaning ARAY is approximately 408% more volatile than SYK relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 2% for IRIDEX Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — IRIX or ARAY or ISRG or GKOS or SYK?

By revenue growth (latest reported year), Glaukos Corporation (GKOS) is pulling ahead at 32.

3% versus -6. 2% for IRIDEX Corporation (IRIX). On earnings-per-share growth, the picture is similar: Accuray Incorporated grew EPS 90. 3% year-over-year, compared to -18. 4% for Glaukos Corporation. Over a 3-year CAGR, GKOS leads at 21. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — IRIX or ARAY or ISRG or GKOS or SYK?

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -37. 0% for Glaukos Corporation — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -17. 1% for GKOS. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is IRIX or ARAY or ISRG or GKOS or SYK more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 28x versus Intuitive Surgical, Inc. 's 1. 99x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Stryker Corporation (SYK) trades at 19. 1x forward P/E versus 43. 3x for Intuitive Surgical, Inc. — 24. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ISRG: 38. 3% to $622. 60.

08

Which pays a better dividend — IRIX or ARAY or ISRG or GKOS or SYK?

In this comparison, SYK (1.

2% yield) pays a dividend. IRIX, ARAY, ISRG, GKOS do not pay a meaningful dividend and should not be held primarily for income.

09

Is IRIX or ARAY or ISRG or GKOS or SYK better for a retirement portfolio?

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 2% yield, +179. 2% 10Y return). Accuray Incorporated (ARAY) carries a higher beta of 2. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +179. 2%, ARAY: -92. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between IRIX and ARAY and ISRG and GKOS and SYK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IRIX is a small-cap quality compounder stock; ARAY is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; GKOS is a small-cap high-growth stock; SYK is a mid-cap quality compounder stock. SYK pays a dividend while IRIX, ARAY, ISRG, GKOS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

IRIX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 22%
Run This Screen
Stocks Like

ARAY

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 16%
Run This Screen
Stocks Like

ISRG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 16%
Run This Screen
Stocks Like

GKOS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 20%
  • Gross Margin > 46%
Run This Screen
Stocks Like

SYK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform IRIX and ARAY and ISRG and GKOS and SYK on the metrics below

Revenue Growth>
%
(IRIX: 7.8% · ARAY: -7.4%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.